Investigational glucagon-like peptide-1 agonists for the treatment of obesity
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
INTRODUCTION: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. AREAS COVERED: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. EXPERT OPINION: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10% of participants stopping therapy due to GI issues [49].”
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10 % of participants stopping therapy due to GI issues [47].”
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10% of participants stopping therapy due to GI issues [49].”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8 mg daily compared to placebo in 9340 high-CV-risk T2DM patients [124].”
BackgroundMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“diabetes mellitus (T2DM) [3] and contributes substantially to the development of hypertension and some cancers [4].”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study was the first CV outcome study with a GLP-1RA to be completed [73].”
BackgroundInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“twice daily in a head-to-head trial [88].”
Global obesity: trends, risk factors and policy implications
Malik, V. S., Willett, W. C., & Hu, F. B. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.199 · Cited by 1,408
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 3×
“once weekly) depending on their half-lives and duration of receptor activation [54,55].”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“with T2DM with overweight or obesity were reported in the SCALE Diabetes study [64].”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“0 mg than with orlistat, and nausea and vomiting occurred more often with liraglutide treatment than with placebo, but this was usually transient and rarely led to discontinuation of treatment [59].”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“Semaglutide (NN9924/OG217SC; Novo Nordisk) is similar in structure to liraglutide and is resistant to degradation by DPP-4 because it is derivatized at lysine 26 [93].”
BackgroundBody-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood
Twig, G., Yaniv, G., Levine, H., Leiba, A., Goldberger, N., Derazne, E., Ben-Ami Shor, D., Tzur, D., Afek, A., Shamiss, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1503840 · Cited by 1,003
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“the controversy with rosiglitazone and the findings with sibutramine [122,123].”
ResultPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“It binds to the GLP-1 receptor (GLP-1R) which is expressed on pancreatic islet α-cells and β-cells and many other tissues including the peripheral and central nervous system [28,29].”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“001) more weight than those on orlistat [60].”
BackgroundRosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“infections and less frequently urinary tract infection and the rare but potentially serious adverse effect of diabetic ketoacidosis without hyperglycemia [126], but overall they are very”
BackgroundA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“0 mg, or placebo for 5 weeks, gastric emptying was reduced at 1 h but not at 5 h with the higher dose of liraglutide, and both doses increased ratings of satiety and fullness and reduced hunger and food consumption with little effect on energy expenditure [43].”
BackgroundDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Schellenberger, V., Wang, C.-W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1588 · Cited by 462
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326
Glaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 2×
“Weight loss with GLP-1RAs not only will contribute to the improvement in glycemic control in T2DM patients, but also can help to correct the lipid abnormalities [44] and reduce blood pressure [45].”
BackgroundSelf-citationGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · cited 1×
“may suggest that targeting these pathways would be a useful goal for future obesity pharmacotherapy [41].”
BackgroundFarr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 1×
“Weight loss with GLP-1RAs not only will contribute to the improvement in glycemic control in T2DM patients, but also can help to correct the lipid abnormalities [44] and reduce blood pressure [45].”
BackgroundHare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 1×
“GLP-1 inhibits glucagon secretion from pancreatic α-cells, either directly or through local stimulation of insulin and somatostatin [33,34].”
BackgroundGlucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Caixas, A., Albert, L., Capel, I., & Rigla, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s55587 · Cited by 236
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Bariatric surgery: Mechanisms, indications and outcomes
O'Brien, P. E. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06391.x · Cited by 214
on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Verpeut, J. L., & Bello, N. T. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.909405 · Cited by 202
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Dushay, J., Gao, C., Gopalakrishnan, G. S., Crawley, M., Mitten, E. K., Wilker, E., Mullington, J., & Maratos-Flier, E. (2012) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 150
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306799110 · Cited by 137
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D. G., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 122
Rosenstock, J., Balas, B., Charbonnel, B. H., Bolli, G. B., Boldrin, M. N., Ratner, R. E., Balena, R., & for the T-emerge 2 Study Group (2012) · Diabetes Care · doi:10.2337/dc12-0709 · Cited by 119
Weight management and current options in pharmacotherapy: Orlistat and sibutramine
Leung, W. Y. S., Thomas, G. N., Chan, J. C. N., & Tomlinson, B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90009-9 · Cited by 107
Self-citationMonami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106 · cited 1×
“confirmed from the completed clinical trials, but ongoing vigilance is required [85,86].”
BackgroundLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY
Unniappan, S., McIntosh, C. H. S., Demuth, H. U., Heiser, U. F., Wolf, R., & Kieffer, T. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0310-8 · Cited by 91
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 88
Henry, R. R., Rosenstock, J., Logan, D. K., Alessi, T. R., Luskey, K. L., & Baron, M. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.009 · Cited by 87
Jensterle, M., Pirš, B., Goričar, K., Dolžan, V., & Janež, A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1868-1 · Cited by 86 · cited 1×
“The GLP-1R rs10305420 polymorphism explained a small part of the interindividual differences in response to liraglutide regarding weight loss in obese women with polycystic ovary syndrome [66].”
BackgroundCardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Fisher, M., Petrie, M. C., Ambery, P., Donaldson, J., Ye, J., & McMurray, J. J. V. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00233-8 · Cited by 85
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84
Dulaglutide: First Global Approval
Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0320-7 · Cited by 75
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Trahair, L. G., Horowitz, M., Stevens, J. E., Feinle‐Bisset, C., Standfield, S., Piscitelli, D., Rayner, C. K., Deane, A. M., & Jones, K. L. (2015) · Diabetologia · doi:10.1007/s00125-015-3638-0 · Cited by 52
Phentermine-topiramate: First combination drug for obesity
Singh, J., & Kumar, R. (2015) · International Journal of Applied and Basic Medical Research · doi:10.4103/2229-516x.157177 · Cited by 51
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 51
Steinert, R. E., Poller, B., Castelli, M. C., Friedman, K., Huber, A. R., Drewe, J., & Beglinger, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.159 · Cited by 47
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 47
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Self-citationGlucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 43
Zhang, L., Zhang, M., Zhang, Y., & Tong, N. (2016) · Scientific Reports · doi:10.1038/srep18904 · Cited by 43
Self-citationUmpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Landó, L. F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Lorcaserin for the treatment of obesity? A closer look at its side effects
DiNicolantonio, J. J., Chatterjee, S., O’Keefe, J. H., & Meier, P. (2014) · Open Heart · doi:10.1136/openhrt-2014-000173 · Cited by 35
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
de Luis, D. A., Ovalle, H. F., Díaz-Soto, G., Izaola, O., de la Fuente, B., & Romero, E. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000032 · Cited by 31
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 28
Emerging GLP-1 receptor agonists
Lund, A., Knop, F. K., & Vilsbøll, T. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.616493 · Cited by 26
Combination phentermine and topiramate for weight maintenance: the first Australian experience
Neoh, S. L., Sumithran, P., Haywood, C. J., Houlihan, C. A., Lee, F., & Proietto, J. (2014) · The Medical Journal of Australia · doi:10.5694/mja13.00193 · Cited by 26
de Luis, D. A., Aller, R., de la Fuente, B., Primo, D., Conde, R., Izaola, O., & Sagrado, M. G. (2014) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21735 · Cited by 24
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1068288 · Cited by 21
Yabe, D., Kuwata, H., Usui, R., Kurose, T., & Seino, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1045471 · Cited by 16
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Egan, J. M., & Chia, C. W. (2014) · Diabetes · doi:10.2337/db13-1909 · Cited by 12
Liraglutide—another weapon in the war against obesity?
Bray, G. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.133 · Cited by 10
SORLI, C. H., Harashima, S., Tsoukas, G. M., Unger, J. R., Karsbøl, J. D., Hansen, T. K., & Bain, S. C. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.017 · Cited by 4
IDRIS, I. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12747 · Cited by 1
Research works printed but not linked: 2
- Baron MA, Buse J, Azeem R, et al. A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes. Diabetologia. 2015;58:S55–S55.
- Henry RR, Rosenstock J, Denham D, et al. Efficacy and tolerability of ITCA 650 (continuous subcutaneous exenatide) for 39 weeks in patients with poorly controlled type 2 diabetes mellitus and high baseline HbA(1c) (>10%). Diabetologia. 2015;58:S378.
Cited by
Targeting autophagy in obesity: from pathophysiology to management
Zhang, Y., Sowers, J. R., & Ren, J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0009-1 · Cited by 338
Self-citationObesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262
“The prominent link between inflammation and obesity has been further emphasized byfinding that theNLRP3 inflammasomemay contribute to the pathology (Stienstra et al., 2010; Vandanmagsar et al., 2011).”
BackgroundMulti-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 178
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“In the trials, GI symptoms rarely led to discontinuation, with < 10 % of participants stopping therapy due to GI issues [47].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
Metadata
- Authors
- Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M.
- Affiliations
- Tongji University (CN)
- Chinese University of Hong Kong (HK)
- Wan Fang Hospital (TW)
- Corresponding author
- Tomlinson, Brian
- Chan, Paul
- Liu, Zhong-Min
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-08-26
- Volume
- 25
- Issue
- 10
- Pages
- 1167-1179
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2508533215
- Cited by
- 25
- References
- 104
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, GLP-1 receptor agonists, liraglutide, type 2 diabetes, obesity pharmacotherapy, weight loss, pancreatitis risk, neoplasms, nausea, gastrointestinal adverse effects, subcutaneous injection, patient adherence, cardiovascular outcomes
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Body Weight, Diabetes Mellitus, Type 2, Humans, Obesity, Drug Design, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.